Detalhe da pesquisa
1.
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.
Blood
; 143(24): 2490-2503, 2024 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38493481
2.
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
Blood
; 141(17): 2127-2140, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36758212
3.
JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality.
Blood
; 137(16): 2139-2151, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33667305
4.
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.
Blood
; 134(21): 1832-1846, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31511238
5.
JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis.
Blood
; 128(6): 839-51, 2016 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27288519
6.
Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.
Blood
; 125(13): 2131-40, 2015 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25595737
7.
Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.
Blood
; 123(25): 3943-50, 2014 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-24820309
8.
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
Blood
; 123(14): 2220-8, 2014 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-24478400
9.
Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.
Blood
; 121(7): 1188-99, 2013 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-23264594
10.
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN.
Blood Adv
; 8(9): 2312-2325, 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38295283
11.
IL-1ß promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells.
Blood Adv
; 8(5): 1234-1249, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38207211
12.
Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.
Hemasphere
; 7(5): e885, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37153874
13.
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
Blood
; 115(10): 2003-7, 2010 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-20061559
14.
Inhibition of interleukin-1ß reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm.
Nat Commun
; 13(1): 5346, 2022 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36100613
15.
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes.
Blood
; 113(8): 1768-77, 2009 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-18845793
16.
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.
Blood
; 113(9): 2022-7, 2009 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-19047681
17.
Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia.
Blood
; 122(22): 3694-6, 2013 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24263960
18.
Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia.
Haematologica
; 99(4): e52-4, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24510341
19.
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
J Clin Invest
; 129(4): 1596-1611, 2019 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30730307
20.
Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.
Blood
; 117(6): 2075-6, 2011 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21310937